Lista de obras - William L Redmond - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

artículo científico publicado en 2019

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

artículo científico publicado en 2020

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

artículo científico publicado en 2018

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice

artículo científico publicado en 2010

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses

scientific article published on 01 January 2007

Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth

artículo científico publicado en 2021

B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets

article

CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles.

artículo científico publicado en 2005

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

artículo científico publicado en 2017

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

artículo científico publicado en 2016

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer.

artículo científico publicado en 2013

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.

artículo científico publicado en 2016

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.

artículo científico publicado en 2014

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity.

artículo científico publicado en 2013

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

artículo científico publicado en 2013

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells

artículo científico publicado en 2014

Cutting edge: T cell-mediated pathology in murine Lyme borreliosis.

artículo científico publicado en 2000

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

artículo científico publicado en 2007

Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC

scientific article published on 01 December 2003

Distinct Requirements for Deletion versus Anergy during CD8 T Cell Peripheral Tolerance In Vivo

artículo científico publicado en 2005

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression

artículo científico publicado en 2012

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

artículo científico publicado en 2016

Editorial: Advances in Combination Tumor Immunotherapy

artículo científico publicado en 2015

How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy.

artículo científico publicado en 2016

Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy

scientific article published on 01 January 2019

Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling

artículo científico publicado en 2018

Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.

artículo científico publicado en 2016

Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development

artículo científico publicado en 2020

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo

artículo científico publicado en 2009

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

scientific article published on 01 May 2020

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

artículo científico publicado en 2015

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor

artículo científico publicado en 2008

Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists

artículo científico publicado en 2018

Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen.

artículo científico publicado en 2001

Professional development session for early career scientists at SITC 2012.

artículo científico publicado en 2013

Signaling through OX40 enhances antitumor immunity

scientific article published on October 2010

The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen

artículo científico publicado en 2008

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor

artículo científico publicado en 2013

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.

artículo científico publicado en 2018

Lista de obras de William L Redmond

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses

Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth

B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets

CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer.

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts.

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity.

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells

Cutting edge: T cell-mediated pathology in murine Lyme borreliosis.

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist

Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC

Distinct Requirements for Deletion versus Anergy during CD8 T Cell Peripheral Tolerance In Vivo

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Editorial: Advances in Combination Tumor Immunotherapy

How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy.

Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy

Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling

Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.

Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor

Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists

Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen.

Professional development session for early career scientists at SITC 2012.

Signaling through OX40 enhances antitumor immunity

The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.